<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Immunology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-3224</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7006814</article-id>
    <article-id pub-id-type="doi">10.3389/fimmu.2020.00107</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Immunology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>FHLdb: A Comprehensive Database on the Molecular Basis of Familial Hemophagocytic Lymphohistiocytosis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Viñas-Giménez</surname>
          <given-names>Laura</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/852981/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Padilla</surname>
          <given-names>Natàlia</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/853130/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Batlle-Masó</surname>
          <given-names>Laura</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
        <xref ref-type="aff" rid="aff5">
          <sup>5</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/828948/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Casals</surname>
          <given-names>Ferran</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/504555/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rivière</surname>
          <given-names>Jacques G.</given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
          <sup>6</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/861582/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Martínez-Gallo</surname>
          <given-names>Mónica</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/506902/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>de la Cruz</surname>
          <given-names>Xavier</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <xref ref-type="aff" rid="aff7">
          <sup>7</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Colobran</surname>
          <given-names>Roger</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="aff" rid="aff8">
          <sup>8</sup>
        </xref>
        <xref ref-type="corresp" rid="c001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/522312/overview"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Research Institute (VHIR), Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB)</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Jeffrey Model Foundation Excellence Center</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff3"><sup>3</sup><institution>Research Unit in Clinical and Translational Bioinformatics, Vall d'Hebron Research Institute (VHIR)</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff4"><sup>4</sup><institution>Servei de Genòmica, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff5"><sup>5</sup><institution>Departament de Ciències Experimentals i de la Salut, Institute of Evolutionary Biology (UPF-CSIC), Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff6"><sup>6</sup><institution>Pediatric Infectious Diseases and Immunodeficiencies Unit (UPIIP), Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB)</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff7"><sup>7</sup><institution>Institut Catala per la Recerca i Estudis Avançats (ICREA)</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <aff id="aff8"><sup>8</sup><institution>Genetics Department, Hospital Universitari Vall d'Hebron (HUVH)</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Jordan Orange, Columbia University, United States</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Udo Zur Stadt, University Medical Center Hamburg-Eppendorf, Germany; Samuel Cern Cher Chiang, Cincinnati Children's Hospital Medical Center, United States</p>
      </fn>
      <corresp id="c001">*Correspondence: Roger Colobran <email>rcolobran@vhebron.net</email></corresp>
      <fn fn-type="other" id="fn001">
        <p>This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology</p>
      </fn>
      <fn fn-type="other" id="fn002">
        <p>†These authors have contributed equally to this work</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>31</day>
      <month>1</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>11</volume>
    <elocation-id>107</elocation-id>
    <history>
      <date date-type="received">
        <day>17</day>
        <month>10</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>1</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2020 Viñas-Giménez, Padilla, Batlle-Masó, Casals, Rivière, Martínez-Gallo, de la Cruz and Colobran.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>Viñas-Giménez, Padilla, Batlle-Masó, Casals, Rivière, Martínez-Gallo, de la Cruz and Colobran</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p><bold>Background:</bold> Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders. The lack of comprehensive disease-specific mutation databases may hinder or delay classification of the genetic variants found in samples from these patients. This is especially true for familial hemophagocytic lymphohistiocytosis (FHL), a life-threatening PID classically considered an autosomal recessive condition, but with increasingly demonstrated genetic heterogeneity.</p>
      <p><bold>Objective:</bold> The aim of this study was to build an open-access repository to collect detailed information on the known genetic variants reported in FHL.</p>
      <p><bold>Methods:</bold> We manually reviewed more than 120 articles to identify all reported variants related to FHL. We retrieved relevant information about the allelic status, the number of patients with the same variant, and whether functional assays were done. We stored all the data retrieved in a PostgreSQL database and then built a website on top of it, using the Django framework.</p>
      <p><bold>Results:</bold> The database designed (FHLdb) (<ext-link ext-link-type="uri" xlink:href="https://www.biotoclin.org/FHLdb">https://www.biotoclin.org/FHLdb</ext-link>) contains comprehensive information on reported variants in the 4 genes related to FHL (<italic>PRF1, UNC13D, STXBP2, STX11</italic>). It comprises 240 missense, 69 frameshift, 51 nonsense, 51 splicing, 10 in-frame indel, 7 deep intronic, and 5 large rearrangement variants together with their allelic status, carrier(s) information, and functional evidence. All genetic variants have been classified as pathogenic, likely pathogenic, uncertain significance, likely benign or benign, according to the American College of Medical Genetics guidelines. Additionally, it integrates information from other relevant databases: clinical evidence from ClinVar and UniProt, population allele frequency from ExAC and gnomAD, and pathogenicity predictions from well-recognized tools (e.g., PolyPhen-2, SIFT). Finally, a diagram depicts the location of the variant relative to the gene exon and protein domain structures.</p>
      <p><bold>Conclusion:</bold> FHLdb includes a broad range of data on the reported genetic variants in familial HLH genes. It is a free-access and easy-to-use resource that will facilitate the interpretation of molecular results of FHL patients, and it illustrates the potential value of disease-specific databases for other PIDs.</p>
    </abstract>
    <kwd-group>
      <kwd>primary immunodeficiency</kwd>
      <kwd>hemophagocytic lymphohistiocytosis</kwd>
      <kwd>database</kwd>
      <kwd>genetics</kwd>
      <kwd>mutation</kwd>
      <kwd>genetic variant</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">Instituto de Salud Carlos III<named-content content-type="fundref-id">10.13039/501100004587</named-content></funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="5"/>
      <table-count count="0"/>
      <equation-count count="0"/>
      <ref-count count="34"/>
      <page-count count="8"/>
      <word-count count="4617"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders affecting the immune system. Most PIDs are considered to have a monogenic cause, but incomplete penetrance, variable expressivity, and interactions between genetic and environmental factors can contribute to their phenotypic diversity. The diagnostic workup for PIDs is based on the patients' clinical manifestations and the results of complex laboratory techniques to guide selection of the candidate gene or genes to be tested (<xref rid="B1" ref-type="bibr">1</xref>). However, because of the diverse nature of these conditions, candidate gene selection is not usually straightforward. Hence, the development of massive parallel sequencing or next-generation sequencing (NGS) is rapidly replacing direct sequencing (Sanger method) as the first-choice method for genetic diagnosis of PIDs (<xref rid="B2" ref-type="bibr">2</xref>). Several NGS-based approaches, from whole-genome sequencing to specific PID panels, are currently in use, and they have led to major breakthroughs in the diagnosis of these disorders (<xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B6" ref-type="bibr">6</xref>).</p>
    <p>Nonetheless, the huge amount of data obtained by NGS technologies makes analysis and interpretation of the results a cumbersome process compared with conventional genetic testing. The clinical significance of a potentially relevant variant may be difficult to ascertain if there is no easily accessible information to consult. Review of the literature is an option, but it can be time-consuming and sometimes, exhausting. The lack of uniform criteria across studies to establish the pathogenicity of genetic variants further complicates this task.</p>
    <p>Disease-specific databases, mainly known as locus-specific databases (LSDBs), may be the best tool to help professionals involved in genetic analysis. LSDBs must be comprehensive in collecting genetic variants relevant for a disease and must be rigorous in providing evidence that supports the role of the variants. Ideally, LSDBs should interact with other established databases and computational tools to depict an overall view of each variant. Unfortunately, LSDBs for PIDs are scarce, often outdated, and not user-friendly. This study was developed when we realized that there was no LSDB for familial hemophagocytic lymphohistiocytosis (FHL), an interesting and complex PID, whose genetic basis is currently under discussion (evolving from classical autosomal recessive inheritance to other models).</p>
    <p>Hemophagocytic lymphohistiocytosis (HLH) comprises a group of rare disorders characterized by a highly stimulated but ineffective immune response that typically produces a massive proinflammatory cytokine storm resulting in fever, pancytopenia, hemophagocytosis, central nervous system (CNS) dysfunction, and multiorgan failure (<xref rid="B7" ref-type="bibr">7</xref>). It most frequently affects infants at early ages, but the disease is also observed in children and adults of all ages. If left untreated, the disease may rapidly progress and lead to death in a few weeks. Treatment for this condition includes immunosuppressive and immune-modulating therapy to control the inflammation and organ damage, but in the most severe cases, hematopoietic stem cell transplantation (HSCT) is the definite cure (<xref rid="B8" ref-type="bibr">8</xref>).</p>
    <p>HLH presents in a wide spectrum of clinical contexts, including fever of unknown origin, acute liver failure, sepsis-like, Kawasaki-like, and neurologic abnormalities (<xref rid="B8" ref-type="bibr">8</xref>). Although a distinctive constellation of clinical and laboratory features has been described for HLH, diagnosis remains challenging as patients may have very different clinical manifestations associated with a variety of triggers (<xref rid="B9" ref-type="bibr">9</xref>). Atypical presentations involving mainly CNS or chronic pathologic inflammation manifestations are examples of such complexity (<xref rid="B10" ref-type="bibr">10</xref>–<xref rid="B12" ref-type="bibr">12</xref>).</p>
    <p>HLH patients are often categorized as having either primary/familial or secondary/sporadic HLH. Familial HLH (FHL) is caused by biallelic mutations in genes involved in the granule-dependent exocytosis pathway, which lead to impaired natural killer (NK) and T-cell cytotoxic activity. To date, 4 genes (<italic>PRF1, UNC13D, STXBP2</italic>, and <italic>STX11</italic>) and 1 genomic region (9q21.3–22) have been identified as candidate causes of FHL2 (<xref rid="B13" ref-type="bibr">13</xref>), FHL3 (<xref rid="B14" ref-type="bibr">14</xref>), FHL4 (<xref rid="B15" ref-type="bibr">15</xref>), FHL5 (<xref rid="B16" ref-type="bibr">16</xref>), and FHL1 (<xref rid="B17" ref-type="bibr">17</xref>), respectively (<xref rid="B18" ref-type="bibr">18</xref>). Other monogenic diseases that produce HLH are Chédiak-Higashi syndrome (<italic>LYST</italic>), Griscelli syndrome type 2 (<italic>RAB27A</italic>), Hermansky-Pudlak syndrome (<italic>AP3B1</italic>), X-linked lymphoproliferative syndrome (XLP)-1 (<italic>SH2D1A</italic>), and XLP-2 (<italic>XIAP</italic>) (<xref rid="B19" ref-type="bibr">19</xref>). HLH can also develop in the absence of familial recurrence and without biallelic mutations in the causal genes, usually in the context of infections, malignancies, and autoinflammatory or metabolic diseases. These are considered “secondary” or “sporadic” HLH (sHLH) (<xref rid="B20" ref-type="bibr">20</xref>). In recent years and coinciding with the rapid evolution of NGS technology, the number of studies reporting new HLH-related variants has significantly increased (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>), and these have elucidated that a proportion of sHLH patients with or without a functional defect harbor monoallelic variants in one of the FHL-related genes (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). In addition, novel types of inheritance have been proposed for HLH, including polygenic and dominant transmission models (<xref rid="B25" ref-type="bibr">25</xref>–<xref rid="B28" ref-type="bibr">28</xref>).</p>
    <p>A percentage of the reported HLH variants can be found in generalist databases such as ClinVar, OMIM (Online Mendelian Inheritance in Man), LOVD (Leiden Open Variation Database), and HGMD (Human Gene Mutation Database). However, these databases may be incomplete, outdated, or not manually curated. As was mentioned, there is no dedicated LSDB for FHL genes, and this may lead to delays in classifying the genetic variants found in FHL patients and, consequently, in their diagnosis and treatment.</p>
    <p>Here, we present FHLdb, a comprehensive database on the molecular basis of familial HLH. FHLdb is a web-based open-access repository of reported variants in the <italic>PRF1, UNC13D, STXBP2</italic>, and <italic>STX11</italic> genes. FHLdb provides detailed information on each variant, including functional evidence of pathogenicity when available, and enables links with other widely used databases (e.g., ClinVar, dbSNP, ExAC, gnomAD) to provide users with the most easily accessible and complete genetic information related to this condition.</p>
  </sec>
  <sec sec-type="methods" id="s2">
    <title>Methods</title>
    <sec>
      <title>Bibliographic Data</title>
      <p>A systematic search in the medical literature retrieved more than 120 related articles, which were manually reviewed to collect all reported variants in FHL patients. Literature search was mainly performed using the Medline database from the National Library of Medicine through the PubMed search engine. PubMed is a free resource supporting the search and retrieval of peer-reviewed scientific literature. Combinations of the following keywords have been used for the search procedure: HLH, FHL, hemophagocytic lymphohistiocytosis, familial hemophagocytic lymphohistiocytosis, hemophagocytic syndrome, PRF1, UNC13D, STXBP2, STX11, mutation, variant, genetic variant, biallelic, monoallelic, heterozygous, homozygous, etc.</p>
      <p>From these studies, we also collected other relevant information to include in FHLdb, such as the reported status of the variant (biallelic and/or monoallelic), whether the variant was found in more than one patient, and whether a functional assay had been carried out to determine the consequences of the variant.</p>
    </sec>
    <sec>
      <title>Database Set-Up</title>
      <p>At the technical level, to guarantee user-friendly access to the data, we stored all information in a PostgreSQL database and then built a website on top of that, using the Django framework. Finally, we completed the information on each variant by providing links to other databases of interest.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <p>FHLdb (<ext-link ext-link-type="uri" xlink:href="https://www.biotoclin.org/FHLdb">https://www.biotoclin.org/FHLdb</ext-link>) is a comprehensive collection of reported variants in the 4 genes known to cause FHL: <italic>PRF1, UNC13D, STXBP2</italic>, and <italic>STX11</italic>. The literature search yielded 433 different variants in these genes, distributed as follows: 240 missense, 69 frameshift, 51 nonsense, 51 splicing, 10 in-frame indel, 7 deep intronic, and 5 large rearrangements (<xref ref-type="fig" rid="F1">Figure 1</xref>). <italic>UNC13D</italic> showed the largest number of variants (189), followed by <italic>PRF1</italic> (157), <italic>STXBP2</italic> (66), and <italic>STX11</italic> (<xref rid="B21" ref-type="bibr">21</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Distribution of genetic variants according to their effect at the protein level. Histograms show the distribution of <italic>STX11, STXBP2, PRF1</italic>, and <italic>UNC13D</italic> variants included in FHLdb. The total number of variants reported in each gene is indicated within parentheses.</p>
      </caption>
      <graphic xlink:href="fimmu-11-00107-g0001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>FHLdb genetic variants in the <italic>UNC13D, PRF1, STXBP2</italic>, and <italic>STX11</italic> genes. Linear representation of UNC13D, PRF1, STXBP2, and STX11 at the protein level. The diagram shows the distribution and location of all variants reported in FHLdb, except for large genomic rearrangements. Dotted lines delimitate each exon. Functional domains are indicated above each gray-scale colored square. MHD1 and MHD2, Munc13 homology domains 1 and 2; SP, signal peptide; MACPF, perforin membrane attack complex; EGF, epidermal growth factor-like; C2, calcium binding domain. The figure was designed using the Protein Paint free software included in the St. Jude PeCan Data Portal (<ext-link ext-link-type="uri" xlink:href="https://pecan.stjude.cloud">https://pecan.stjude.cloud</ext-link>) (<xref rid="B29" ref-type="bibr">29</xref>).</p>
      </caption>
      <graphic xlink:href="fimmu-11-00107-g0002"/>
    </fig>
    <p>Each variant was manually curated, and we followed the Human Genome Variation Society (HGVS) guidelines for variant nomenclature (<ext-link ext-link-type="uri" xlink:href="http://varnomen.hgvs.org">http://varnomen.hgvs.org</ext-link>) to obtain a harmonized, interchangeable, clear dataset. We found that the nomenclature of 29% of the variants was incomplete or did not follow these guidelines in their original description; hence, these variants were renamed (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>). In this manuscript, both “mutation” and “variant” terms have been used. While both terms indicate a change in the nucleotide sequence, in medicine “mutation” is used to indicate a sequence variant associated with a disease phenotype. On the other hand, the current guidelines of authoritative organizations recommend using neutral terms like “variant” followed by a classification term like pathogenic, benign, etc. (see HGVS website for extended discussion about terminology). Therefore, we preferably used “variant” and restricted the use of “mutation” in some specific cases to indicate disease-causing variants.</p>
    <p>The allelic status of each variant is reported in the following terms: biallelic, when it was reported in homozygous or compound heterozygous state, and monoallelic. Thus, a variant can be reported as biallelic, monoallelic, or both. Although most variants are found in biallelic state, because of the recessive inheritance of these 4 genes, a significant percentage (ranging from 12 to 36%) were reported as monoallelic (<xref ref-type="fig" rid="F3">Figure 3</xref>), which indicates the increasingly recognized role of monoallelic variants in FHL (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>). However, caution must be exercised in evaluating the role of monoallelic variants: FHL is essentially an autosomal recessive disease and there is only one well-described example of monoallelic variants as disease causing mutations through a dominant-negative mechanism (<xref rid="B28" ref-type="bibr">28</xref>). The other reported monoallelic variants in FHL are not proven to be disease causing by itself but may represent susceptibility/risk factors in genetic predisposition to FHL (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Distribution of genetic variants according their allelic status. Histograms show the distribution of variants in the <italic>STX11, STXBP2, PRF1</italic>, and <italic>UNC13D</italic> genes included in FHLdb. The total number of variants reported in each gene is indicated within parentheses.</p>
      </caption>
      <graphic xlink:href="fimmu-11-00107-g0003"/>
    </fig>
    <p>We also reviewed whether functional assays had been carried out to decipher the functional consequences of the variant. This is one of the main challenges in the interpretation of genetic variants, especially those that are not clearly related to loss of function (e.g., missense variants). Variants with reported functional studies are indicated and the corresponding reference is provided.</p>
    <p>To help the interpretation, we manually classified all genetic variants according to the American College of Medical Genetics (ACMG) guidelines. ACMG recommends a five-tier system of classification using a specific standard terminology: pathogenic, likely pathogenic, uncertain significance, likely benign and benign (<xref rid="B31" ref-type="bibr">31</xref>).</p>
    <p>FHLdb integrates information from other widely used databases, such as clinical evidence from ClinVar and UniProt, and population allele frequency from ExAC and gnomAD, and it provides computational pathogenicity predictions from PolyPhen-2, CADD, PON-P2, and SIFT. We found that 91% of the missense variants were predicted to be pathogenic by at least one <italic>in silico</italic> predictor, and 96% of the variants had an allele frequency below 1% in the ExAC database. Remarkably, only 20% of variants were included in the ClinVar database, the largest resource to support clinical variant interpretation. This finding indicates that there is still little available information in ClinVar about FHL genetic variants, and it underscores the need for disease-specific databases.</p>
    <p>All the information obtained was compiled in an open, user-friendly website (<ext-link ext-link-type="uri" xlink:href="https://www.biotoclin.org/FHLdb">https://www.biotoclin.org/FHLdb</ext-link>), divided into three main parts. First, there is a welcome page presenting the database, where the user finds the 4 genes typically associated with FHL (<italic>PRF1, UNC13D, STXBP2, STX11</italic>), a description of the information available for each variant, and other general information. Second, after selecting the gene of interest, the user is transferred to the gene view page where all variants are listed and the main characteristics are shown (<xref ref-type="fig" rid="F4">Figure 4</xref>). Third, a link to more detailed information located in the last column allows the user to access a section about the specific variant, which includes the following: (<xref rid="B1" ref-type="bibr">1</xref>) a summary of the references (at least the first) describing the variant, whether the variant has been reported as biallelic and/or monoallelic, whether it was found in more than 1 patient, and whether a functional assay was carried out; (<xref rid="B2" ref-type="bibr">2</xref>) the <italic>in silico</italic> pathogenicity predictions (CADD, PolyPhen-2, PON-P2, and SIFT); (<xref rid="B3" ref-type="bibr">3</xref>) links to other databases of interest regarding the specific variant (ClinVar, UniProt, dbSNP, Ensembl, ExAC, Gnomad) and databases containing general knowledge about the disease, the gene, and the protein (e.g., Decipher, GeneReviews, OMIM, GeneCards, NCBI); and (<xref rid="B4" ref-type="bibr">4</xref>) a diagram showing the location of the variant in the protein (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
    <fig id="F4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Example of the gene view page where all variants are listed and their main characteristics described. The <italic>PRF1</italic> gene view page is shown. The variant indicated by the pointer is highlighted in gray (in this example, c.445G&gt;A).</p>
      </caption>
      <graphic xlink:href="fimmu-11-00107-g0004"/>
    </fig>
    <fig id="F5" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Example of the detailed information page, containing specific information about a variant. A missense variant in the <italic>PRF1</italic> gene is shown.</p>
      </caption>
      <graphic xlink:href="fimmu-11-00107-g0005"/>
    </fig>
  </sec>
  <sec id="s4">
    <title>Concluding Remarks</title>
    <p>To our knowledge, this is the first LSDB for FHL syndrome. A prototypical definition of LSDB is “a collection of sequence variants in a specific gene(s) that causes a Mendelian disorder or change in phenotype” (<xref rid="B32" ref-type="bibr">32</xref>). FHLdb is intended to collect all known variants in the 4 genes typically associated with familial HLH published in peer-reviewed literature. Beyond simply listing all reported variants in the <italic>PRF1, UNC13D, STXBP2</italic>, and <italic>STX11</italic> genes, FHLdb includes other relevant data, such as the variant frequency in the general population, computational prediction of pathogenicity, and functional evidence. Additionally, it provided links to external reference databases to enable users to easily access all available related resources.</p>
    <p>To build FHLdb, we followed general consensus recommendations to enable broad and easy to manage use (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). FHLdb is an open-access resource, licensed under the Creative Commons Attribution-ShareAlike (4.0) International License, which allows users to adapt, remix, transform, and build upon the material for any purpose, even commercial intents, under the terms specified in the full-text license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-sa/4.0/legalcode">https://creativecommons.org/licenses/by-sa/4.0/legalcode</ext-link>). All existing data in FHLdb can be downloaded in a user-friendly format (txt) and in other programming languages (e.g., Python, Curl, or Wget).</p>
    <p>Curation is one of the greatest strengths of LSDBs and is likely the aspect that most differentiates them from general databases (<xref rid="B34" ref-type="bibr">34</xref>). Each variant in FHLdb was manually curated and almost one third of entries were renamed to adapt the nomenclature to the HGVS. We decided to include only genetic variants supported by peer-reviewed, indexed articles. Therefore, each variant has at least one associated article where the user can find further information beyond that included in FHLdb.</p>
    <p>It is important that LSDB creators accept a long commitment and continued updating of the database. In our case, FHL/HLH is a strategic research field in our laboratory. We are currently working on two research projects focused on HLH, funded by Instituto de Salud Carlos III in Spain (see funding section), and we are determined to keep FHLdb updated in the future. To accomplish that, we will be alert to new publications on the genetic basis of HLH and we encourage users to report on a new variant by sending us the article describing it.</p>
    <p>In this first version of FHLdb, we focused on genes involved in the cytotoxic pathway. Other genes causing congenital immunodeficiency syndromes that are associated with HLH (e.g., <italic>NLRC4, LYST, RAB27A, SH2D1A, XIAP</italic>) have not as yet been reported but it is planned to include them in FHLdb in the near future, expanding the data base to a compilation of genetic variants associated to HLH. The increasing use of NGS is rapidly expanding the number of genetic variants found in HLH patients. Implementation of FHLdb aims to help scientists and clinicians working in the field in their search for FHL-related genetic variants to support their research and daily clinical practice.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>Publicly available datasets were analyzed in this study. All data is available in <ext-link ext-link-type="uri" xlink:href="http://www.biotoclin.org/FHLdb/">http://www.biotoclin.org/FHLdb/</ext-link>.</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>LV-G performed the literature search, selection, and manual curation of the genetic variant data, and wrote part of the manuscript. NP adjusted the variants to the HGVS guidelines, performed the technical database set-up and web development, and wrote part of the manuscript. LB-M, FC, JR, MM-G, and XC collaborated in the database design and literature search. RC was responsible for designing the study, supervising the literature search and database set-up, writing the manuscript, and approving the final draft. All authors reviewed the manuscript and contributed to the final draft.</p>
    <sec>
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </sec>
</body>
<back>
  <ack>
    <p>We acknowledge Celine Cavallo for the English language support.</p>
  </ack>
  <fn-group>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding.</bold> This study was funded by <italic>Instituto de Salud Carlos III</italic>, grants PI17/00660 and PI18/00346, cofinanced by the European Regional Development Fund (ERDF). LB-M is supported by a <italic>Formació de Personal Investigador</italic> (FPI) fellowship from Generalitat de Catalunya (2018_FI_B00072). FC was funded by grants SAF2015-68472-C2-2-R from the Ministerio de Economía y Competitividad (Spain) and FEDER (EU) and RTI2018-096824-B-C22 from the Spanish Ministry of Science, Innovation and Universities co-financed by ERDF (FC), and by Direcció General de Recerca, Generalitat de Catalunya (2014SGR-866 and 2017SGR-702).</p>
    </fn>
  </fn-group>
  <sec sec-type="supplementary-material" id="s7">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.00107/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.00107/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SM1">
      <label>Supplementary Table 1</label>
      <caption>
        <p>Variants renamed in FHLdb according the HGVS guidelines.</p>
      </caption>
      <media xlink:href="Table_1.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Jeddane</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Ailal</surname><given-names>F</given-names></name><name><surname>Bobby Gaspar</surname><given-names>H</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>The 2017 IUIS phenotypic classification for primary immunodeficiencies</article-title>. <source>J Clin Immunol</source>. (<year>2018</year>) <volume>38</volume>:<fpage>129</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-017-0465-8</pub-id><?supplied-pmid 29226301?><pub-id pub-id-type="pmid">29226301</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seleman</surname><given-names>M</given-names></name><name><surname>Hoyos-Bachiloglu</surname><given-names>R</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name></person-group>. <article-title>Uses of next-generation sequencing technologies for the diagnosis of primary immunodeficiencies</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>847</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00847</pub-id><?supplied-pmid 28791010?><pub-id pub-id-type="pmid">28791010</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rae</surname><given-names>W</given-names></name><name><surname>Ward</surname><given-names>D</given-names></name><name><surname>Mattocks</surname><given-names>C</given-names></name><name><surname>Pengelly</surname><given-names>RJ</given-names></name><name><surname>Eren</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>SV</given-names></name><etal/></person-group>. <article-title>Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics</article-title>. <source>Clin Genet</source>. (<year>2018</year>) <volume>93</volume>:<fpage>647</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1111/cge.13163</pub-id><?supplied-pmid 29077208?><pub-id pub-id-type="pmid">29077208</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mousa</surname><given-names>H</given-names></name><name><surname>Abouelhoda</surname><given-names>M</given-names></name><name><surname>Monies</surname><given-names>DM</given-names></name><name><surname>Al-Tassan</surname><given-names>N</given-names></name><name><surname>Al-Ghonaium</surname><given-names>A</given-names></name><name><surname>Al-Saud</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2016</year>) <volume>137</volume>:<fpage>1780</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2015.12.1310</pub-id><?supplied-pmid 26915675?><pub-id pub-id-type="pmid">26915675</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>V</given-names></name><name><surname>Dotta</surname><given-names>L</given-names></name><name><surname>Giardino</surname><given-names>G</given-names></name><name><surname>Cirillo</surname><given-names>E</given-names></name><name><surname>Lougaris</surname><given-names>V</given-names></name><name><surname>D'Assante</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Diagnostics of primary immunodeficiencies through next-generation sequencing</article-title>. <source>Front Immunol</source>. (<year>2016</year>) <volume>7</volume>:<fpage>466</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00466</pub-id><?supplied-pmid 27872624?><pub-id pub-id-type="pmid">27872624</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cifaldi</surname><given-names>C</given-names></name><name><surname>Brigida</surname><given-names>I</given-names></name><name><surname>Barzaghi</surname><given-names>F</given-names></name><name><surname>Zoccolillo</surname><given-names>M</given-names></name><name><surname>Ferradini</surname><given-names>V</given-names></name><name><surname>Petricone</surname><given-names>D</given-names></name><etal/></person-group><article-title>Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>316</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01184</pub-id><pub-id pub-id-type="pmid">31031743</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gholam</surname><given-names>C</given-names></name><name><surname>Grigoriadou</surname><given-names>S</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Gaspar</surname><given-names>HB</given-names></name></person-group>. <article-title>Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management</article-title>. <source>Clin Exp Immunol</source>. (<year>2011</year>) <volume>163</volume>:<fpage>271</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2010.04302.x</pub-id><?supplied-pmid 21303357?><pub-id pub-id-type="pmid">21303357</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>MB</given-names></name><name><surname>Allen</surname><given-names>CE</given-names></name><name><surname>Weitzman</surname><given-names>S</given-names></name><name><surname>Filipovich</surname><given-names>AH</given-names></name><name><surname>McClain</surname><given-names>KL</given-names></name></person-group>. <article-title>How I treat hemophagocytic lymphohistiocytosis</article-title>. <source>Blood</source>. (<year>2011</year>) <volume>118</volume>:<fpage>4041</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2011-03-278127</pub-id><?supplied-pmid 21828139?><pub-id pub-id-type="pmid">21828139</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>MB</given-names></name><name><surname>Allen</surname><given-names>CE</given-names></name><name><surname>Greenberg</surname><given-names>J</given-names></name><name><surname>Henry</surname><given-names>M</given-names></name><name><surname>Hermiston</surname><given-names>ML</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)</article-title>. <source>Pediatr Blood Cancer</source>. (<year>2019</year>) <volume>66</volume>:<fpage>e27929</fpage>. <pub-id pub-id-type="doi">10.1002/pbc.27929</pub-id><?supplied-pmid 31339233?><pub-id pub-id-type="pmid">31339233</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giardino</surname><given-names>G</given-names></name><name><surname>De Luca</surname><given-names>M</given-names></name><name><surname>Cirillo</surname><given-names>E</given-names></name><name><surname>Palma</surname><given-names>P</given-names></name><name><surname>Romano</surname><given-names>R</given-names></name><name><surname>Valeriani</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Two brothers with atypical UNC13D-related hemophagocytic lymphohistiocytosis characterized by massive lung and brain involvement</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>1892</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.01892</pub-id><?supplied-pmid 29312353?><pub-id pub-id-type="pmid">29312353</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>J</given-names></name><name><surname>Ménasché</surname><given-names>G</given-names></name><name><surname>Callebaut</surname><given-names>I</given-names></name><name><surname>Minard-Colin</surname><given-names>V</given-names></name><name><surname>Bader-Meunier</surname><given-names>B</given-names></name><name><surname>Le Clainche</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Severe and progressive encephalitis as a presenting manifestation of a novel missense perforin mutation and impaired cytolytic activity</article-title>. <source>Blood</source>. (<year>2005</year>) <volume>105</volume>:<fpage>2658</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-09-3590</pub-id><?supplied-pmid 15598808?><pub-id pub-id-type="pmid">15598808</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Grom</surname><given-names>AA</given-names></name><name><surname>Behrens</surname><given-names>EM</given-names></name><name><surname>Cron</surname><given-names>RQ</given-names></name></person-group>. <article-title>Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment</article-title>. <source>Genes Immun</source>. (<year>2012</year>) <volume>13</volume>:<fpage>289</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/gene.2012.3</pub-id><?supplied-pmid 22418018?><pub-id pub-id-type="pmid">22418018</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepp</surname><given-names>SE</given-names></name><name><surname>Dufourcq-Lagelouse</surname><given-names>R</given-names></name><name><surname>Le Deist</surname><given-names>F</given-names></name><name><surname>Bhawan</surname><given-names>S</given-names></name><name><surname>Certain</surname><given-names>S</given-names></name><name><surname>Mathew</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Perforin gene defects in familial hemophagocytic lymphohistiocytosis</article-title>. <source>Science</source>. (<year>1999</year>) <volume>286</volume>:<fpage>1957</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1126/science.286.5446.1957</pub-id><?supplied-pmid 10583959?><pub-id pub-id-type="pmid">10583959</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>J</given-names></name><name><surname>Callebaut</surname><given-names>I</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Certain</surname><given-names>S</given-names></name><name><surname>Bacq</surname><given-names>D</given-names></name><name><surname>Dumont</surname><given-names>C</given-names></name><name><surname>Lambert</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3)</article-title>. <source>Cell</source>. (<year>2003</year>) <volume>115</volume>:<fpage>461</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(03)00855-9</pub-id><?supplied-pmid 14622600?><pub-id pub-id-type="pmid">14622600</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>zur Stadt</surname><given-names>U</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Kasper</surname><given-names>B</given-names></name><name><surname>Beutel</surname><given-names>K</given-names></name><name><surname>Diler</surname><given-names>AS</given-names></name><name><surname>Henter</surname><given-names>J-I</given-names></name><etal/></person-group>. <article-title>Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11</article-title>. <source>Hum Mol Genet</source>. (<year>2005</year>) <volume>14</volume>:<fpage>827</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi076</pub-id><?supplied-pmid 15703195?><pub-id pub-id-type="pmid">15703195</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>zur Stadt</surname><given-names>U</given-names></name><name><surname>Rohr</surname><given-names>J</given-names></name><name><surname>Seifert</surname><given-names>W</given-names></name><name><surname>Koch</surname><given-names>F</given-names></name><name><surname>Grieve</surname><given-names>S</given-names></name><name><surname>Pagel</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11</article-title>. <source>Am J Hum Genet</source>. (<year>2009</year>) <volume>85</volume>:<fpage>482</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2009.09.005</pub-id><?supplied-pmid 19804848?><pub-id pub-id-type="pmid">19804848</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohadi</surname><given-names>M</given-names></name><name><surname>Lalloz</surname><given-names>MR</given-names></name><name><surname>Sham</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Dearlove</surname><given-names>AM</given-names></name><name><surname>Shiach</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping</article-title>. <source>Am J Hum Genet</source>. (<year>1999</year>) <volume>64</volume>:<fpage>165</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1086/302187</pub-id><?supplied-pmid 9915955?><pub-id pub-id-type="pmid">9915955</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janka</surname><given-names>GE</given-names></name><name><surname>Lehmberg</surname><given-names>K</given-names></name></person-group><article-title>Hemophagocytic syndromes–an update</article-title>. <source>Blood Rev</source>. (<year>2014</year>) <volume>28</volume>:<fpage>135</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2014.03.002</pub-id><pub-id pub-id-type="pmid">24792320</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetica</surname><given-names>V</given-names></name><name><surname>Pende</surname><given-names>D</given-names></name><name><surname>Griffiths</surname><given-names>GM</given-names></name><name><surname>Aricò</surname><given-names>M</given-names></name></person-group>. <article-title>Molecular basis of familial hemophagocytic lymphohistiocytosis</article-title>. <source>Haematologica</source>. (<year>2010</year>) <volume>95</volume>:<fpage>538</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2009.019562</pub-id><?supplied-pmid 20378576?><pub-id pub-id-type="pmid">20378576</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janka</surname><given-names>GE</given-names></name></person-group>. <article-title>Hemophagocytic syndromes</article-title>. <source>Blood Rev</source>. (<year>2007</year>) <volume>21</volume>:<fpage>245</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2007.05.001</pub-id><?supplied-pmid 17590250?><pub-id pub-id-type="pmid">17590250</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesi</surname><given-names>B</given-names></name><name><surname>Lagerstedt-Robinson</surname><given-names>K</given-names></name><name><surname>Chiang</surname><given-names>SCC</given-names></name><name><surname>Ben Bdira</surname><given-names>E</given-names></name><name><surname>Abboud</surname><given-names>M</given-names></name><name><surname>Belen</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis</article-title>. <source>Genome Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>130</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-015-0244-1</pub-id><?supplied-pmid 26684649?><pub-id pub-id-type="pmid">26684649</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinn</surname><given-names>IK</given-names></name><name><surname>Eckstein</surname><given-names>OS</given-names></name><name><surname>Peckham-Gregory</surname><given-names>EC</given-names></name><name><surname>Goldberg</surname><given-names>BR</given-names></name><name><surname>Forbes</surname><given-names>LR</given-names></name><name><surname>Nicholas</surname><given-names>SK</given-names></name><etal/></person-group>. <article-title>Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis</article-title>. <source>Blood</source>. (<year>2018</year>) <volume>132</volume>:<fpage>89</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2017-11-814244</pub-id><?supplied-pmid 29632024?><pub-id pub-id-type="pmid">29632024</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetica</surname><given-names>V</given-names></name><name><surname>Sieni</surname><given-names>E</given-names></name><name><surname>Pende</surname><given-names>D</given-names></name><name><surname>Danesino</surname><given-names>C</given-names></name><name><surname>De Fusco</surname><given-names>C</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2016</year>) <volume>137</volume>:<fpage>188</fpage>–<lpage>96</lpage>.e4. <pub-id pub-id-type="doi">10.1016/j.jaci.2015.06.048</pub-id><?supplied-pmid 26342526?><pub-id pub-id-type="pmid">26342526</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X-J</given-names></name><name><surname>Wang</surname><given-names>H-S</given-names></name><name><surname>Ju</surname><given-names>X-L</given-names></name><name><surname>Xiao</surname><given-names>P-F</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>H-M</given-names></name><etal/></person-group>. <article-title>Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study</article-title>. <source>Pediatr Blood Cancer</source>. (<year>2017</year>) <volume>64</volume>:<fpage>e26264</fpage>. <pub-id pub-id-type="doi">10.1002/pbc.26264</pub-id><?supplied-pmid 27781387?><pub-id pub-id-type="pmid">27781387</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Chandrakasan</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>H</given-names></name><name><surname>Valencia</surname><given-names>CA</given-names></name><name><surname>Husami</surname><given-names>A</given-names></name><name><surname>Kissell</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis</article-title>. <source>Blood</source>. (<year>2014</year>) <volume>124</volume>:<fpage>1331</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2014-05-573105</pub-id><?supplied-pmid 24916509?><pub-id pub-id-type="pmid">24916509</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group>. <article-title>Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis</article-title>. <source>Int J Hematol</source>. (<year>2015</year>) <volume>102</volume>:<fpage>488</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/s12185-015-1807-z</pub-id><?supplied-pmid 25980904?><pub-id pub-id-type="pmid">25980904</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Bracaglia</surname><given-names>C</given-names></name><name><surname>Prencipe</surname><given-names>G</given-names></name><name><surname>Bemrich-Stolz</surname><given-names>CJ</given-names></name><name><surname>Beukelman</surname><given-names>T</given-names></name><name><surname>Dimmitt</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>A Heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis</article-title>. <source>J Immunol</source>. (<year>2016</year>) <volume>196</volume>:<fpage>2492</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1501284</pub-id><?supplied-pmid 26880764?><pub-id pub-id-type="pmid">26880764</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spessott</surname><given-names>WA</given-names></name><name><surname>Sanmillan</surname><given-names>ML</given-names></name><name><surname>McCormick</surname><given-names>ME</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Villanueva</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion</article-title>. <source>Blood</source>. (<year>2015</year>) <volume>125</volume>:<fpage>1566</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2014-11-610816</pub-id><?supplied-pmid 25564401?><pub-id pub-id-type="pmid">25564401</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Edmonson</surname><given-names>MN</given-names></name><name><surname>Wilkinson</surname><given-names>MR</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Exploring genomic alteration in pediatric cancer using ProteinPaint</article-title>. <source>Nat Genet</source>. (<year>2016</year>) <volume>48</volume>:<fpage>4</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3466</pub-id><?supplied-pmid 26711108?><pub-id pub-id-type="pmid">26711108</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieni</surname><given-names>E</given-names></name><name><surname>Cetica</surname><given-names>V</given-names></name><name><surname>Hackmann</surname><given-names>Y</given-names></name><name><surname>Coniglio</surname><given-names>ML</given-names></name><name><surname>Da Ros</surname><given-names>M</given-names></name><name><surname>Ciambotti</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<fpage>167</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00167</pub-id><?supplied-pmid 24795715?><pub-id pub-id-type="pmid">24795715</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><name><surname>Bick</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source>. (<year>2015</year>) <volume>17</volume>:<fpage>405</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id><?supplied-pmid 25741868?><pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotton</surname><given-names>RGH</given-names></name><name><surname>Auerbach</surname><given-names>AD</given-names></name><name><surname>Beckmann</surname><given-names>JS</given-names></name><name><surname>Blumenfeld</surname><given-names>OO</given-names></name><name><surname>Brookes</surname><given-names>AJ</given-names></name><name><surname>Brown</surname><given-names>AF</given-names></name><etal/></person-group>. <article-title>Recommendations for locus-specific databases and their curation</article-title>. <source>Hum Mutat</source>. (<year>2008</year>) <volume>29</volume>:<fpage>2</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/humu.20650</pub-id><?supplied-pmid 18157828?><pub-id pub-id-type="pmid">18157828</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vihinen</surname><given-names>M</given-names></name><name><surname>den Dunnen</surname><given-names>JT</given-names></name><name><surname>Dalgleish</surname><given-names>R</given-names></name><name><surname>Cotton</surname><given-names>RGH</given-names></name></person-group>. <article-title>Guidelines for establishing locus specific databases</article-title>. <source>Hum Mutat</source>. (<year>2012</year>) <volume>33</volume>:<fpage>298</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21646</pub-id><?supplied-pmid 22052659?><pub-id pub-id-type="pmid">22052659</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>J</given-names></name><name><surname>Dalgleish</surname><given-names>R</given-names></name><name><surname>Vihinen</surname><given-names>M</given-names></name><name><surname>Taschner</surname><given-names>PEM</given-names></name><name><surname>den Dunnen</surname><given-names>JT</given-names></name></person-group>. <article-title>Curating gene variant databases (LSDBs): toward a universal standard</article-title>. <source>Hum Mutat</source>. (<year>2012</year>) <volume>33</volume>:<fpage>291</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21626</pub-id><?supplied-pmid 21990126?><pub-id pub-id-type="pmid">21990126</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
